5-methylformononetin | 128672-43-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 5-methylformononetin
• 英文别名: 7-Hydroxy-3-(4-methoxyphenyl)-5-methylchromen-4-one
• CAS: 128672-43-5
• 化学式: C₁₇H₁₄O₄
• mdl: MFCD07808367
• 分子量: 282.296
• InChiKey: UKNAHPHZOVNWLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 5-methylformononetin 、 3-哌啶甲酸 在 4-二甲氨基吡啶 作用下， 以 乙醇 为溶剂， 以91%的产率得到1-{[7-hydroxy-3-(4-methoxyphenyl)-5-methyl-4-oxo-4H-chromen-8-yl]methyl}piperidine-3-carboxylic acid
  参考文献：
  名称：

  Synthesis of amino-acid derivatives of formononetin and cladrin

  摘要：

  研究了氨基酸对天然异黄酮的氨基甲基化作用。找到了选择性生产 N-(4H-4-氧代苯并吡喃-8-基)甲基取代氨基酸的条件。

  DOI：

  10.1007/s10600-012-0313-2
• 作为产物：
  描述：

  1-(2,4-dihydroxy-6-methylphenyl)-2-(4-methoxyphenyl)-ethanone 生成 5-methylformononetin
  参考文献：
  名称：

  YUE, BAOZHEN;ZHOU, ZEWEI;CAI, MENGSHEN, GAODEHN SYUEHSYAO XUASYUEH SYUEHBAO, 11,(1990) N, S. 99-101

  摘要：

  DOI：

文献信息

• Synthesis of cytisine derivatives of flavonoids. 2. Aminomethylation of 7-hydroxyisoflavones
  作者：S. P. Bondarenko、M. S. Frasinyuk、V. I. Vinogradova、V. P. Khilya

  DOI：10.1007/s10600-011-0006-2

  日期：2011.9

  Aminomethylation of natural 7-hydroxyisoflavones and their analogs by the alkaloid (−)cytisine was studied. Substituted 8-(cytisin-12-yl)methyl-7-hydroxyisoflavones were synthesized.

  研究了生物碱 (−) 金雀花碱对天然 7-羟基异黄酮及其类似物的氨甲基化作用。合成了取代的8-(金雀花素-12-基)甲基-7-羟基异黄酮。
• ANTI-VIRAL COMPOUNDS
  申请人：Iadonato Shawn P.

  公开号：US20110262482A1

  公开（公告）日：2011-10-27

  Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

  本文披露了用于治疗病毒感染的化合物和相关组合物，包括RNA病毒感染，并且可以调节脊椎动物细胞中的RIG-I通路的化合物，包括可以激活RIG-I通路的化合物。
• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.
• US9408826B2
  申请人：——

  公开号：US9408826B2

  公开（公告）日：2016-08-09
• [EN] ANTI-VIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：KINETA INC

  公开号：WO2011133728A2

  公开（公告）日：2011-10-27

  Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.